drugset / Trial / NCT07663747
Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC
Phase 2
Not yet recruiting
56 enrolled
The Netherlands Cancer Institute
Astellas Pharma Inc · collabMerck Sharp & Dohme LLC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 2 clinical intervention trial to assess efficacy of induction EVP to spare the bladder in stage T2-4aN0-1 urothelial bladder cancer (UBC), using a response-adapted approach
Timeline
- Start
- 2026-09-01
- Primary completion
- 2031-04-01
- Completion
- 2032-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enfortumab Vedotin | Other / unclassified | 1.25 mg/kg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 400 mg | — |